MedTrace Logo

Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping

NCT04928690 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2021-06-16

No results posted yet for this study

Summary

The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease, specifically in Mild Cognitive Impairment (MCI) and cognitively normal (CN) cohorts; and whether similar algorithms can predict cognitive functioning, in classifying MCI vs CN.

Conditions

Sponsors & Collaborators

  • Novoic Limited

    lead INDUSTRY

Principal Investigators

  • Emil Fristed, MSc · Novoic Ltd

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-20
Primary Completion
2021-08-15
Completion
2022-08-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928690 on ClinicalTrials.gov